

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
10 February 2005 (10.02.2005)

PCT

(10) International Publication Number
WO 2005/012220 A3

(51) International Patent Classification⁷: **C07C 59/72**,
235/34, C07D 207/333, 335/02, 211/60, 309/22, C07C
233/25, 43/295, C07F 9/142, C07C 317/22, A61K 31/192,
31/165, 31/40, 31/382, 31/44

(21) International Application Number:
PCT/US2004/024308

(22) International Filing Date: 27 July 2004 (27.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/490,588 28 July 2003 (28.07.2003) US

(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, Philadelphia, PA 19101
(US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BRITTON**,
Jonathan, E. [US/US]; GlaxoSmithKline, Five Moore
Drive, P.O. Box 13398, Research Triangle Park, NC
27709 (US). **FANG**, Jing [CN/US]; GlaxoSmithKline,
Five Moore Drive, P.O. Box 13398, Research Triangle
Park, NC 27709 (US). **HEYER**, Dennis [US/US]; Glaxo-
SmithKline, Five Moore Drive, P.O. Box 13398, Research
Triangle Park, NC 27709 (US). **MILLER**, Aaron, Bayne
[US/US]; GlaxoSmithKline, Five Moore Drive, P.O. Box
13398, Research Triangle Park, NC 27709 (US). **NAVAS**,
Frank, III [US/US]; GlaxoSmithKline, Five Moore Drive,
P.O. Box 13398, Research Triangle Park, NC 27709
(US). **SMALLEY**, Terrence, Lee, Jr. [US/US]; Glaxo-
SmithKline, Five Moore Drive, P.O. Box 13398, Research

Triangle Park, NC 27709 (US). **ZUERCHER**, William, J.
[US/US]; GlaxoSmithKline, Five Moore Drive, P.O. Box
13398, Research Triangle Park, NC 27709 (US). **KATAM-
REDDY**, Subba, Reddy [IN/US]; GlaxoSmithKline, Five
Moore Drive, P.O. Box 13398, Research Triangle Park,
NC 27709 (US).

(74) Agents: **LEVY**, David, J. et al.; GlaxoSmithKline, Five
Moore Drive, P.O. Box 13398, Research Triangle Park, NC
27709 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).


Published:

— with international search report

(88) Date of publication of the international search report:
24 March 2005

[Continued on next page]

(54) Title: CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF ESTROGEN RECEPTOR



(57) Abstract: The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substituted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation. Formula (I) including salts, solvates, and pharmacologically functional derivatives thereof wherein R¹ is OH; each of R² and R⁴ independently are selected from OH, alkyl, or halogen; each of p and q independently are selected from 0, 1, or 2; R³ is -(Y)_z-R⁶; z is 0 or 1; Y is -C=C- or CR⁶=CR¹-; X is -(CH₂)_n- where n is 0, 1, 2, or 3, -C(R⁹)₂-, -O-, or -S-.



(48) Date of publication of this corrected version:

19 May 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(15) Information about Correction:

see PCT Gazette No. 20/2005 of 19 May 2005, Section II